Related Experiment Videos
Systematic Trial for Evaluating Docetaxel in a Human Prostate Cancer Cell DU145 Xenograft Model
Miyuki Mabuchi1,2, Masahiro Ueda1,2, Yuri Yoshida1,2
1School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan.
Abstract:
The inhibitory activities of docetaxel at a wide range of doses (0.1-10 mg/kg; subcutaneously (s.c.), once/week) in nude mice bearing a human prostate cancer cell (DU145), xenograft model with implantation of DU145 cells or a DU145 solid tumor were examined. This systematic trial demonstrated that (i) docetaxel was more effective in the xenograft model formed by implantation of DU145 cells than in the solid DU145 tumor; (ii) administration of 2.5 mg/kg docetaxel was the critical dose because inhibitory activities were not observed at 2.5 mg/kg, while they were noted at 5 mg/kg and 10 mg/kg in both implantation approaches; (iii) edema-like effects (plump body shape and legs) were observed in both groups at 2.5 mg/kg and the tumor sizes, often increased by blood plasma and other fluids, as well as body weights were higher than at other doses; and (iv) suppression of body weight gain was observed at 10 mg/kg docetaxel.
Insights
Docetaxel showed varying efficacy against prostate cancer models in mice. A dose of 2.5 mg/kg was critical, with higher doses (5-10 mg/kg) demonstrating inhibitory activity, while lower doses caused edema-like effects.
Area of Science:
- Oncology
- Pharmacology
- Preclinical Research
Background:
- Prostate cancer remains a significant health concern.
- Docetaxel is a key chemotherapeutic agent used in prostate cancer treatment.
- Understanding docetaxel's efficacy and dose-dependent effects in preclinical models is crucial for optimizing treatment strategies.
Purpose of the Study:
- To evaluate the inhibitory activities of docetaxel against human prostate cancer DU145 xenografts in nude mice.
- To determine the optimal effective dose and identify potential dose-limiting toxicities.
- To compare docetaxel's efficacy in different DU145 xenograft models (cell implantation vs. solid tumor).
Main Methods:
- Administration of docetaxel at doses ranging from 0.1 to 10 mg/kg subcutaneously once weekly.
- Utilized nude mice bearing either DU145 cell xenografts or established DU145 solid tumors.
- Monitored tumor growth, body weight, and observed for any adverse or edema-like effects.
Main Results:
- Docetaxel demonstrated greater efficacy in the xenograft model derived from DU145 cell implantation compared to the solid tumor model.
- A dose of 2.5 mg/kg was identified as a critical threshold; no inhibition was observed, but edema-like effects occurred.
- Significant tumor inhibition was observed at 5 mg/kg and 10 mg/kg, with dose-dependent suppression of body weight gain noted at 10 mg/kg.
Conclusions:
- Docetaxel's efficacy against prostate cancer xenografts is model-dependent.
- The 2.5 mg/kg dose represents a threshold where efficacy is lost, and adverse effects may emerge.
- Higher doses of docetaxel (5-10 mg/kg) are effective in inhibiting tumor growth but require careful monitoring for weight suppression.